Diagnosis and/or therapy of tumours using monoclonal antibodies specific for the human IL-4 receptor
AssigneeRoyal Postgraduate Medical School of Hammersmith Hospital
InventorsMary Alice Ritter, Mark Larche
Life of this patent
Estimating the term…
Abstract
The invention provides compounds for use in the diagnosis and/or therapy of tumors and/or as an immunosuppressant agent selected from the group consisting of antibodies which bind to IL-4 receptors and IL-4 receptor-binding fragments thereof. A preferred such compound is monoclonal antibody MR6 produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. The invention also extends to the use of the compounds for in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation and to a novel protein of molecular weight 200,000 daltons functioning as a receptor for IL-4.
Claims26
A method for the diagnosis of tumours characterised by elevated expression of an about 200,000 dalton protein which binds to antibody produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with accession number 88033002;
- wherein said method comprises administering to a human subject an effective amount of an agent selected from the group consisting of an antibody which specifically binds to the about 200,000 dalton protein, a fragment of said antibody which is capable of specifically binding to said 200,000 dalton protein, and mixtures thereof, whereby said agent becomes bound to said about 200,000 dalton protein of said tumours;
- and then detecting the presence of said agent bound on or in said tumours.
A method of therapy of tumors characterized by elevated expression of an about 200,000 dalton protein which binds to antibody produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with accession number 88033002. wherein said method comprises administering to a human subject a therapeutically effective amount of an agent selected from the group consisting of an antibody which specifically binds to the about 200,000 dalton protein, a fragment of said antibody which is capable of specifically binding to said 200,000 dalton protein, and mixtures thereof.
A method of therapy of an activated immune response characterized by elevated levels of expression of an about 200,000 dalton protein on cells involved in the immune response wherein a human subject is administered an effective amount of an agent selected from the group consisting of an antibody which specifically binds to the about 200,000 dalton protein, a fragment of said antibody which is capable of specifically binding to said 200,000 dalton protein, and mixtures thereof;
- with the proviso that said 200,000 dalton protein binds to antibody produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with accession number 88033002.
A method for achieving antigen-specific immunosuppression in a human subject in vivo or in human cells or tissues in vitro wherein said human subject, cells or tissues are administered antigen for presentation and are subsequently administrated an effective amount of an agent selected from the group consisting of an antibody which specifically binds to an about 200,000 dalton protein, a fragment of said antibody which is capable of specifically binding to said 200,000 dalton protein, and mixtures thereof, wherein the cells to be immunosuppressed are specific for the presented antigen and are characterized by elevated levels of expression of said 200,000 dalton protein;
- with the proviso that said 200,000 dalton protein binds to antibody produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with accession number 88033002.
Dependencies are inferred from the claim text.